1130875

Averitas Pharma, Inc. — FEI 3016404674

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
September 16, 2020
Fiscal Year
2020
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Morristown, NJ (United States)

Additional Details

Postmarket Adverse Drug Experience (PADE)